Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Recruiting · Phase 2 · NCT06865105
Conditions: Psoriatic Arthritis
At a glance
- Research payments reported, 2025
- $663,283
- U.S. investigators named
- 15
- Sites paid
- 14
- Planned or actual enrollment
- 300
About the trial
- Sponsor
- AbbVie
- Tested
- Lutikizumab (drug), Risankizumab (drug), ABBV-701 (drug), ABBV-547 (drug)
- Dates
- Started 2025-04-11; completion 2029-08
- Results posted
- Not yet
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy…
From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $663,283 in research payments for this study in 2025 (81 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christine T. Thai, M.D. Rheumatology · Huntington Beach, CA
- Michael S. Thakor, MD Rheumatology · Fort Collins, CO
- John Carter, MD Rheumatology · Tampa, FL
- Rodney S. Daniel, MD MSCR Rheumatology · Oldsmar, FL
- Elias Halpert, MD Rheumatology · Tamarac, FL
- Alexander Torres, MD Rheumatology · Avon Park, FL
- Angela R. Crowley, M.D. Rheumatology · Willowbrook, IL
- Robert A. Hozman, M.D. Rheumatology · Skokie, IL
- Steven J. Klein, MD Rheumatology · Hagerstown, MD
- Isam Diab, MD Rheumatology · Middleburg Hts, OH
- Alan Kivitz, MD Rheumatology · Duncansville, PA
- Ramesh C. Gupta I, M.D. Specialist · Memphis, TN
- Shaikh Ali, MD PA Rheumatology · Tomball, TX
- Paul K. Pickrell, MD Rheumatology · Austin, TX
- Philip A. Waller, M.D. Rheumatology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dynamed Clinical Research LP $165,621
- Clinical Research of West Florida $116,938
- Tekton Research LLC $114,770
- Shelby Research LLC $49,125
- Harac Research $34,436
- Accurate Clinical Research Inc $33,272
- Altoona Center for Clinical Researc $30,883
- West Broward Rheumatology Associate $26,153
- Newport Huntington Medical Group $19,105
- Paramount Medical Research $18,500
- Willow Rheumatology and Wellness $16,579
- Clin Investigation Specialists Inc $13,500
- Hmd Research LLC $12,300
- Klein and Associates MD PA $12,103
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.